English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 25 May 2015, 13:00 HKT/SGT
Share:
    

Source: National Institute for Materials Science (NIMS)
Nano-capsules Designed for Diagnosing Malignant Tumours
Japanese researchers have developed adaptable nano-capsules that can help in the diagnosis of glioblastoma cells - a highly invasive form of brain tumours.

TSUKUBA, Japan, May 25, 2015 - (ACN Newswire) - Polymersomes are hollow, synthetic, nano-sized capsules. They have been extensively studied for their potential in the targeted delivery of drugs within the body. PICsomes[1] are a novel class of polymersomes that were recently developed in Japan. They are made by mixing electrolyte groups formed of positively and negatively charged ions. PICsomes can survive in the bloodstream for long periods and can be used to deliver water-soluble substances to target tissues.

Nano-capsules designed for diagnosing malignant tumours

A study published in Science and Technology of Advanced Materials (STAM) reports that PICsomes can be adapted to last longer in the bloodstream and to better target specific sites in tumours. These "functionalized" PICsomes have great potential for use in both drug delivery and in the magnetic resonance imaging of tumours.

Cyclic RGD (cRGD) - a peptide or short chain of amino acids - is known to specifically bind to two receptors that play a significant role in the formation of new blood vessels in tumours. This makes it a good tumour tracer. In the STAM study, Japanese researchers bound cRGD to PICsomes. The cRGD-PICsomes were then intravenously injected into mice that had been inoculated - under the skin - with human glioblastoma cells, a highly invasive brain tumour. The research team found that the cRGD-PICsomes accumulated mainly in the new blood vessels of the tumour and that they remained near these blood vessels 24 hours later.

The researchers then loaded cRGD-PICsomes with superparamagnetic iron oxide (SPIO), which is used to improve the visibility of internal body structures in magnetic resonance imaging. In addition, glioblastoma cells were injected into the brains of mice and allowed to grow for more than two weeks. The SPIO-loaded cRGD-PICsomes were then intravenously injected into the mice. Using magnetic imaging, the team successfully tracked the loaded PICsomes in new blood vessels that formed around the glioblastomas.

Previous research has shown that magnetic imaging can detect SPIO-loaded PICsomes that are not bound with cRGD in vascular-rich tumours such as tumours of the colon. But they can't always be detected in glioblastomas: brain tumours that are strongly protected by the blood-brain barrier, which prevents both toxic substances and drugs from reaching the brain.

The results of the study suggest that SPIO-loaded cRGD-PICsomes might be useful for enhancing the contrast during magnetic resonance imaging in tumour microenvironments, including in new blood vessels that overexpress cRGD-sensitive transmembrane receptors.

Because blood vessel formation is intimately related to tumour malignancy, magnetic resonance imaging using PICsomes that are adapted to target tumour blood vessels could be a promising tool for the accurate diagnosis of malignant tumours.

[1] Polyethylene glycol-conjugated polyion complex vesicles

For further information contact:

Professor Kazunori Kataoka
Department of Bioengineering and
Center for Disease Biology and Integrative Medicine
The University of Tokyo, Japan
Email: kataoka@bmw.t.u-tokyo.ac.jp

More information about the research paper:

Science and Technology of Advanced Materials [Volume 16 Issue 3 (2015) 035004]
http://iopscience.iop.org/1468-6996/16/3/035004/article
doi:10.1088/1468-6996/16/3/035004/

"Density-tunable conjugation of cyclic RGD ligands with polyion complex vesicles for the neovascular imaging of orthotopic glioblastomas"

Kawamura, W., Miura, Y., Kokuryo, D., Toh, K., Yamada, N., Nomoto, T., Matsumoto, Y., Sueyoshi, D., Liu, X., Aoki, I., Kano, M.R., Nishiyama, N., Saga, T., Kishimura, A. and Kataoka K.

Journal Information

Science and Technology of Advanced Materials (STAM) is the leading open access, international journal for outstanding research articles across all aspects of materials science. Our audience is the international materials community across the disciplines of materials science, physics, chemistry, biology as well as engineering.

The journal covers a broad spectrum of materials science research including functional materials, synthesis and processing, theoretical analyses, characterization and properties of materials. Emphasis is placed on the interdisciplinary nature of materials science and issues at the forefront of the field, such as energy and environmental issues, as well as medical and bioengineering applications. http://iopscience.iop.org/1468-6996

For more information about the journal Science and Technology of Advanced Materials, contact

Mikiko Tanifuji
Publishing Director
Science and Technology of Advanced Materials
Email: TANIFUJI.Mikiko@nims.go.jp


Press release distributed by ResearchSEA for National Institute for Materials Science.

Topic: Research and development
Source: National Institute for Materials Science (NIMS)

Sectors: Science & Research, BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

National Institute for Materials Science (NIMS) Related News
2020年2月17日 15時33分 JST
Using Bone's Natural Electricity to Promote Regeneration
Feb 19, 2015 10:30 HKT/SGT
Controlling Car Pollution at the Quantum Level
Jan 30, 2015 13:00 HKT/SGT
Understanding the reinforcing ability of carbon nanotubes
Jan 23, 2015 15:00 HKT/SGT
Improvements in Transistors Will Make Flexible Plastic Computers a Reality
Aug 15, 2014 12:00 HKT/SGT
Carbon Nanotubes and Near-infrared Lasers Promise a Cost Effective Solution for Cell Membrane Manipulation
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575